Ken Griffin Magenta Therapeutics, Inc. Call Options Transaction History

Citadel Advisors LLC

  • $505 Billion
  • Q3 2024

Call Options

3 transactions
Quarter Operation Price Per call calls change calls Held SEC Form
Q2 2023

Aug 14, 2023
SELL
$0.62 - $0.79 $496 - $632
-800 Reduced 5.37%
14,100 $10,000
Q1 2023

May 15, 2023
SELL
$0.41 - $0.86 $4,469 - $9,374
-10,900 Reduced 42.25%
14,900 $11,000
Q4 2022

Feb 14, 2023
BUY
$0.36 - $1.59 $9,288 - $41,022
25,800 New
25,800 $10,000

Others Institutions Holding MGTA

# of Institutions
2
Shares Held
442K
Call Options Held
0
Put Options Held
0
View Full List

About Magenta Therapeutics, Inc.

MGTA Quotes by TradingView
  • Ticker MGTA
  • Exchange NASDAQ
  • Sector Healthcare
  • Industry Biotechnology
  • Shares Outstandng 58,890,500
  • Description
  • Magenta Therapeutics, Inc., a clinical-stage biotechnology company, develops medicines to bring the curative power of stem cell transplants to patients with blood cancers, genetic diseases, and autoimmune diseases. It develops MGTA-117, an anti-CD117 antibody that targets hematopoietic stem cells (HSCs) and genetically mutated stem cells that ca...
More about MGTA
Track Ken Griffin's Portfolio

Track Ken Griffin Portfolio

Follow Ken Griffin (Citadel Advisors LLC) and customize your updates to receive the information that matters most to you.

Portfolio Update

Get notified when there are updates to the investment portfolio of Citadel Advisors LLC, based on Form 13F filings with the SEC.

News

Stay updated on Citadel Advisors LLC and Ken Griffin with notifications on news.

Choose your preferred platform and Sign Up 👇 Telegram Email